154 related articles for article (PubMed ID: 21403007)
1. Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis.
Gilli F; Navone ND; Perga S; Marnetto F; Caldano M; Capobianco M; Pulizzi A; Malucchi S; Bertolotto A
Arch Neurol; 2011 Jul; 68(7):879-88. PubMed ID: 21403007
[TBL] [Abstract][Full Text] [Related]
2. Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.
Navone ND; Perga S; Martire S; Berchialla P; Malucchi S; Bertolotto A
J Neuroimmunol; 2014 Jul; 272(1-2):99-102. PubMed ID: 24852325
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
4. Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis.
Gilli F; Lindberg RL; Valentino P; Marnetto F; Malucchi S; Sala A; Capobianco M; di Sapio A; Sperli F; Kappos L; Calogero RA; Bertolotto A
PLoS One; 2010 Jan; 5(1):e8962. PubMed ID: 20126412
[TBL] [Abstract][Full Text] [Related]
5. SOCS gene family expression profile in the blood of multiple sclerosis patients.
Toghi M; Taheri M; Arsang-Jang S; Ohadi M; Mirfakhraie R; Mazdeh M; Sayad A
J Neurol Sci; 2017 Apr; 375():481-485. PubMed ID: 28196747
[TBL] [Abstract][Full Text] [Related]
6. Association of TNFAIP3 and TNFRSF1A variation with multiple sclerosis in a German case-control cohort.
Hoffjan S; Okur A; Epplen JT; Wieczorek S; Chan A; Akkad DA
Int J Immunogenet; 2015 Apr; 42(2):106-10. PubMed ID: 25684197
[TBL] [Abstract][Full Text] [Related]
7. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
8. Zinc-ion binding and cytokine activity regulation pathways predicts outcome in relapsing-remitting multiple sclerosis.
Achiron A; Gurevich M; Snir Y; Segal E; Mandel M
Clin Exp Immunol; 2007 Aug; 149(2):235-42. PubMed ID: 17488294
[TBL] [Abstract][Full Text] [Related]
9. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Johnson BH; Bonafede MM; Watson C
CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055
[TBL] [Abstract][Full Text] [Related]
10. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
[TBL] [Abstract][Full Text] [Related]
12. The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
McKay FC; Gatt PN; Fewings N; Parnell GP; Schibeci SD; Basuki MA; Powell JE; Goldinger A; Fabis-Pedrini MJ; Kermode AG; Burke T; Vucic S; Stewart GJ; Booth DR
Clin Immunol; 2016 Feb; 163():96-107. PubMed ID: 26762769
[TBL] [Abstract][Full Text] [Related]
13. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
15. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in the CIITA -168A/G (rs3087456) and CIITA +1614G/C (rs4774) may influence severity in multiple sclerosis patients.
Pereira VCSR; Fontes-Dantas FL; Paradela ER; Malfetano FR; Scherpenhuijzen SSB; Mansur LF; Luiz RR; Oliveira AP; Farinhas JGD; Maiolino Â; Alves-Leon SV
Arq Neuropsiquiatr; 2019 Mar; 77(3):166-173. PubMed ID: 30970129
[TBL] [Abstract][Full Text] [Related]
17. Analysis of T2 intensity by magnetic resonance imaging of deep gray matter nuclei in multiple sclerosis patients: effect of immunomodulatory therapies.
Pawate S; Wang L; Song Y; Sriram S
J Neuroimaging; 2012 Apr; 22(2):137-44. PubMed ID: 21707826
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation and alterations of genes involved in NFκB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer.
Ungerbäck J; Belenki D; Jawad ul-Hassan A; Fredrikson M; Fransén K; Elander N; Verma D; Söderkvist P
Carcinogenesis; 2012 Nov; 33(11):2126-34. PubMed ID: 22843550
[TBL] [Abstract][Full Text] [Related]
19. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
[TBL] [Abstract][Full Text] [Related]
20. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
Link J
Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
